Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The company was founded in 2000 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.

- Actimab-A displayed robust MDSC depletion at statistically superior levels to other CD33-targeted therapeutics, including unconjugated Lintuzumab and Mylotarg™ - Myeloid derived suppressor cells (MDSCs) are ubiquitous across multiple cancer indications and exert strongly immunosuppressive effects through inhibition of immune responses by T cells, B cells and NK cells - Data support the potential for Actimab-A to be a backbone therapy to broadly improve antitumor activity of immunotherapies and other therapeutic modalities in multiple solid tumor indications NEW YORK , April 19, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced today the first ever data demonstrating the utility of Actimab-A to depleted myeloid derived suppressor cells (MDSCs), which are ubiquitously present within the solid tumor microenvironment as well as blood cancers. The new data were showcased in a poster presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting, which is being held April 14 - 19, 2023 in Orlando, Florida.

Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual Meeting

ATNM has finally delivered complete data from SIERRA, and it is solid. They are going to file later this year.

Actinium: Highly Derisked Late Stage Molecule With Successful Trial

-  Announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in r/r AML patients ages 55+; achieved primary endpoint of dCR with high statistical significance (p

Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones

-  First ever data demonstrating the novel application of Actimab-A to enhance antitumor immune activity by depleting MDSCs, a population of highly immunosuppressive cells closely associated with poor clinical outcomes in cancer -  New solid tumor program data including the first exploration of the effects of targeting HER3 with either alpha (225Ac)- or beta (177Lu)- emitting radiotherapeutics in ovarian and colorectal cancer models, demonstrating potent anti-cancer activity NEW YORK , March 16, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced today that two abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting being held April 14 - 19, 2023 in Orlando, Florida. The abstracts highlight the multifaceted anti-cancer activity of CD33-targeted clinical-stage asset Actimab-A and enhanced anti-tumor effect of HER3-targeted, radiotherapy being developed in collaboration with AVEO Oncology, an LG Chem Company.

Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting

NEW YORK , March 15, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company's management team will participate in a virtual presentation at Oppenheimer's 33rd Annual Healthcare Conference being held March 13-17, 2023. The presentation will include recent Company highlights including positive results from its pivotal Phase 3 SIERRA trial of Iomab-B and development opportunities for Actimab-A under the recently signed Cooperative Research and Development Agreement with the National Cancer Institute (NCI).

Actinium Pharmaceuticals, Inc. to Present at Oppenheimer's 33rd Annual Healthcare Conference

- KOL webinar on Tuesday, February 28, 2023, at 8 a.m. EST - Actinium intends to file a BLA for Iomab-B in 2H:2023 following positive SIERRA trial results - Actinium reiterates current cash and cash equivalents of approximately $100 million are projected to fund operations through 2025 NEW YORK , Feb. 27, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will host a key opinion leader (KOL) webinar at 8 a.m.

Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL Webinar

Actinium has lofty ambitions to change the landscape of leukemia treatment. But ATNM stock cratered this week on final-phase test results.

Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth

-  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

-  Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results -  Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK , Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19, 2023 at the World Center Marriott in Orlando, Florida. Actinium will host an investor conference call and webcast to present full topline results from its pivotal Phase 3 SIERRA trial of Iomab-B at 6:00 PM EST on Saturday, February 18, 2023.

Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023

-  National Cancer Institute will sponsor and oversee clinical trials of Actimab-A under the terms of the Cooperative Research and Development Agreement -  Collaboration will provide Actimab-A and other necessary support to study Actimab-A alone or in combinations with chemotherapy, immunotherapy and/or targeted agents aligned with Actinium's development strategy -  Over 2,000 institutions within NCI funded extramural clinical networks will have access to Actimab-A for conducting clinical and non-clinical research and development -  CRADA Clinical Studies will be performed utilizing NCI's Experimental Therapeutics Clinical Trials Network (ETCTN) and National Clinical Trials Network (NCTN) NEW YORK , Feb. 6, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes for Health (NIH), to develop Actimab-A for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. Under the terms of the CRADA, the NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A while Actinium will be responsible for supplying and distributing Actimab-A to participating clinical sites and providing additional support as needed.

Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies

NEW YORK , Jan. 17, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company's management team will participate in a fireside chat on Thursday, January 19, 2023 at 10:30 AM EST at the 3rd Annual B. Riley Securities Oncology Conference.

Actinium Pharmaceuticals, Inc. to Present at the 3rd Annual B. Riley Securities Oncology Conference

NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that data from its pivotal Phase 3 SIERRA trial of Iomab-B have been accepted as a late-breaker presentation at the Transplantation & Cellular Therapy (TCT) Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). TCT, the largest bone marrow transplant (BMT) focused medical conference globally, is being held February 15 – 19, 2023 at the World Center Marriott in Orlando, Florida.

Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings

Actinium Pharmaceuticals is delivering the goods on a deep pipeline of therapeutics. It has deepened its bench with experienced operators.

Actinium Pharmaceuticals: Prep For February

-  59% 1-year overall survival and 32% 2-year overall survival in patients with prior Venetoclax treatment -  52% 1-year overall survival and 19% 2-year overall survival in patients with a TP53 mutation -  75% measurable residual disease negativity achieved in heavily pretreated, high-risk relapsed or refractory patients -  Actimab-A + CLAG-M was well tolerated with a manageable safety profile NEW YORK , Dec. 12, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today highlighted high rates of Complete Remission (CR/CRi) and rates of measurable residual disease (MRD) negativity with improved overall survival in its Actimab-A CLAG-M combination trial in high-risk patients with relapsed or refractory (r/r) acute myeloid leukemia (AML). These data were detailed in an oral presentation at the 64th Annual ASH Meeting & Symposium being held December 10-13, 2022 in New Orleans, Louisiana.

Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH

- Collaboration builds on the groundbreaking research of Columbia University oncologist Dr. Siddhartha Mukherjee that uses gene-editing to remove the CD33 surface protein from hematopoietic stem cells - Actimab-A to be used post-transplant of these engineered stem cells to prevent relapse by selectively targeting residual CD33 positive leukemia cells while sparing the engineered stem cells - High rates of measurable residual disease negativity demonstrated by Actimab-A + CLAG-M validates merits of Actimab-A's use to prevent disease relapse post gene edited stem cell transplant - Actimab-A + CLAG-M data to be presented in oral presentation at American Society of Hematology Annual Meeting on Saturday, December 10 th highlighting 53% 1-year and 32% 2-year overall survival, 67% Overall Response Rate and 72% MRD negativity in patients with relapsed or refractory acute myeloid leukemia NEW YORK , Dec. 8, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced that it has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Dr. Siddhartha Mukherjee, MD, DPhil, Assistant Professor of Medicine at Columbia University Medical Center in the Department of Medicine and Division of Hematology/Oncology and his research group developed the technology.

Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 Negative

53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches Patients on study received a median of 2 lines of prior therapy with 57% receiving prior treatment with venetoclax and 67% had adverse cytogenetics with 52% of patients having a TP53 mutation Data accepted for oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting & Symposium on Saturday, December 10 th at 10:30 AM CT NEW YORK , Nov. 3, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today highlighted positive results from the Phase 1 trial evaluating Actimab-A with salvage chemotherapy regimen CLAG-M in fit patients with relapsed or refractory acute myeloid leukemia (AML) that is being conducted at the Medical College of Wisconsin as investigator sponsored study. These data were detailed in an abstract accepted for oral presentation at the 64th Annual ASH Meeting & Symposium being held December 10-13, 2022 in New Orleans, Louisiana.

Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial

-Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology-Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK , Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development assets with revenues in excess of a billion dollars.

Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization

Shares of Actinium Pharmaceuticals Inc. ATNM, +24.20% were up 22.8% in trading on Monday after the company met the primary endpoint in a Phase 3 clinical trial for its investigational treatment for relapsed or refractory acute myeloid leukemia. Actinium said it plans to share additional clinical data by the end of the year.

Actinium's stock jumps 22% on new data for its acute myeloid leukemia therapy

Actinium Pharmaceuticals (NYSEMKT: ATNM ) stock is gaining on Monday after posting positive results from a Phase 3 clinical trial. The point of this clinical trial was to determine the effectiveness of Iomab-B in treating patients suffering from Elderly Relapsed or Refractory AML.

Actinium (ATNM) Stock Pops on Positive Trial Results

-  Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a p-value of

Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Riding two powerful franchises (Iomab and Actimab), Actinium Pharmaceuticals is brewing a deep pipeline of therapeutics for multiple indications. There is also AWE Technology that is developed in collaboration with other biotech innovators.

Actinium: Overview Of A Promising Innovator

Key hires with proven expertise and track records in Bone Marrow Transplant, Acute Myeloid Leukemia, Radiation Sciences and Clinical Operations position Actinium well to drive key clinical programs forward NEW YORK , Oct. 27, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced a broad senior level expansion of its clinical organization.  These key hires strengthen the Company's expertise in hematological malignancies, bone marrow transplant (BMT) and radiation sciences as well its operational capabilities.

Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A

Actinium (ATNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?

NEW YORK , Oct. 26, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today announced that it will be participating in the Bio-Europe conference being held virtually November 2 – 4, 2022. Members of Actinium's business development team will be participating in 1-on-1 meetings during the conference.

Actinium Pharmaceuticals to Participate in the 2022 Bio-Europe Conference

Jenny Hsieh joins Actinium as Chief Strategy Officer from Gilead Sciences, following its acquisition of Immunomedics Sunitha Lakshminarayanan, Senior Vice President, Head of CMC and Product Development, joins from Bristol Myers Squibb, and significantly strengthens team with high-impact hires Stephen Dressel brings nearly 20 years of finance and commercial experience from Regeneron and high-growth biotechnology companies NEW YORK , Oct. 25, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today highlighted multiple additions to its senior leadership team including Jenny Hsieh as Chief Strategy Officer, Sunitha Lakshminarayanan, as Senior Vice President, Head of CMC and Product Development, and Stephen Dressel as Vice President, Strategic Finance and Analysis. In addition, Sunitha has fortified the company's CMC organization and capabilities with Directors, Peter Baker, PhD, and Micah Riskin, MS, MBA, who respectively managed production and site expansion efforts for the radiotherapies Pluvicto® and Lutathera® at Novartis and supported clinical and commercial cellular therapy products at Bristol-Myers Squibb.

News for Actinium Pharmaceuticals Stock (ATNM)